كسترال XL ١٠ ملغ

Pays: Israël

Langue: arabe

Source: Ministry of Health

Ingrédients actifs:

ALFUZOSIN HYDROCHLORIDE 10 MG

Disponible depuis:

SANOFI - AVENTIS ISRAEL LTD

Code ATC:

G04CA01

forme pharmaceutique:

TABLETS PROLONGED RELEASE

Mode d'administration:

PER OS

Fabriqué par:

SANOFI WINTHROP INDUSTRIE, FRANCE

Groupe thérapeutique:

ALFUZOSIN

indications thérapeutiques:

Treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. Adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.

Date de l'autorisation:

2011-07-01

Notice patient

1986±Ε΍ΈΟΣΗΓϢΔϞΩΎͿΛϞ΍ΔϢΥϦ΃ΏΟϬϢΑϘϠϬΗΓϢϠϞΓΈΗϦ
ρϘϓΏϳΑρΔϔλϭϖϓϭ˯΍ϭΩϟ΍ϕ
˷
ϭγ
˵
ϳ
ΏϠϢ 10 XLϜ΍ΈΗΎΓϚ
Ω
˴
ΗϢ
˵
ϢΈͿΈΣΗΕ΍ΫΙ΍ΈϏ΃
ώϠϣ 10 HCIϥϳγϭίϭϔϟ΃ϰϠϋ
Ω
˴
Ηϣ
˵
ϣέϳέΣΗϱΫιέϗϝϛϱϭΗΣϳ
.alfuzosin HCI 10 mg
."Δ
˷
ϳϓΎο·ΕΎϣϭϠόϣ"
6ϝλϔϟ΍έυϧ΍ΔϳγΎγΣϟ΍ΕΎΑΑγ
˵
ϣϭΔϟΎ
˷
όϔϟ΍έϳϏ
˷
Ω΍ϭϣϟ΍ .˯΍ϬΩϞ΍ϜΎϢΌΗΓΎΑ˯ΩΑϞ΍ϜΑϏϘϞΫϬΎϬΗͿΎϬϦΚΗΣϤ
˷
ΌϢΗΑΓΈΗϦϞ΍΃ΈϏ΍
ϪΟϭΗϓ ˬΔϳϓΎο· ΔϠ΋γ΃ ϙϳΩϟ ΕϧΎϛ ΍Ϋ·
˯΍ϭ
˷
Ωϟ΍ ϥϋ ΓίΟϭϣ ΕΎϣϭϠόϣ ϰϠϋ Γέηϧϟ΍ ϩΫϫ
ϱϭΗΣΗ
ϲϟΩϳλϟ΍ϭ΃ΏϳΑρϟ΍ϰϟ·
ϥϳΑϪΑΎηΗϙϟ΍ΩΑϭϟϰΗΣˬϡϫ
˷
έοϳΩϗϪ
˷
ϧϷ˭ϥϳέΧ϶ϟϪ
˶
ρόΗϻϙϠΟ΃ϥϣ˯΍ϭΩϟ΍΍Ϋϫϑ
˶
λ
˵
ϭ
ϝΎΟέϠϟ
˷
Ωόϣ˯΍ϭΩϟ΍ϡϬΗϟΎΣϭΔ
˷
ϳΣλϟ΍ϙΗϟΎΣ
Δϧγ16ϥγϥϭΩϥϳϘϫ΍έϣϟ΍ϭϝΎϔρϷ΍ΝϼόϟιλΧϣέϳϏ˯΍ϭΩϟ΍΍Ϋϫ
ˮ˯΍Ϭ
˷
ΩϞ΍΍ΫϪ
˷
ΩΫ΃
˴
ϠϞ1
έΧ΄Ηϟ΍ΩϧϋΎϣϳγϻˬΩϳϣΣϟ΍prostateΕΎΗγϭέΑϟ΍ϡΧοΗν΍έϋ΃Νϼόϟ
ϝ΍έΗΎγϛϝϣόΗγ
˵
ϳ
ΔΟϳΗϧΩΎΣϟ΍ϝϭΑϟ΍αΎΑΗΣ΍ϲϓˬέΎρ
˸
Λ
˶
ϗΓέργϘϠϟϲϠϳϣϛΗΝϼόϛϭˬΔϳΣ΍έΟΔϳϠϣϋ˯΍έΟ·ϲϓ
.ΩϳϣΣϟ΍ ΕΎΗγϭέΑϟ΍ϡΧοΗ
ΔͿΟϼΌϞ΍ΔΫϬϢΟϢϞ΍
ϲ΋ΎϘΗϧ΍ έλΣϣ ϭϫϭ ˬΎϔϟ΃ Ε΍έλΣ
˵
ϣϰϋΩ
˵
ΗΕ΍έοΣΗγϣΔϋϭϣΟϣϰϟ·XLϝ΍έΗΎγϛϲϣΗϧϳ
ΩΣ΍ϭΎϔϟ΃ĮϝΑϘΗγϣϠϟ
˯΍ϬΩϞ΍ϜΎϢΌΗΓ΍ϜΑϏ2
˯΍ϬΩϞ΍ϜΎϢΌΗΓ΍ΪϦϢ
˵
Ϳ
 x
.(6ϝλϔϟ΍έυϧ΍˯΍ϭΩϟ΍ΕΎΑϛέϣΩΣϷϭ΃ϥϳγϭίϭϔϟϷΔϳΟέ΃ΔϳγΎγΣϙϳΩϟΕϧΎϛ΍Ϋ·
 x
OrthostaticϲΑΎλΗϧϻ΍ϡΩϟ΍ρϐονΎϔΧϧ΍ϥϣϲοΎϣϟ